Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
PN6047 was also completely devoid of adverse events typically associated with conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or untoward effects following withdrawal symptoms. This validates the unique preclinical profile of PN6047, which shows that it acts very selectively on the delta opioid receptor, distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
With the Phase I trial's final report at hand and after fruitful discussions with clinical Key Opinion Leaders on designing the Phase IIa Proof of Concept study, PharmNovo is well-prepared to move PN6047 into the next stages of clinical testing.
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
PN6047 was also completely devoid of adverse events typically associated with conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or untoward effects following withdrawal symptoms. This validates the unique preclinical profile of PN6047, which shows that it acts very selectively on the delta opioid receptor, distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
With the Phase I trial's final report at hand and after fruitful discussions with clinical Key Opinion Leaders on designing the Phase IIa Proof of Concept study, PharmNovo is well-prepared to move PN6047 into the next stages of clinical testing.
Latest news
View all
PharmNovo live at neurology theme event at RedEye
Per von Mentzer, CEO, presented PN6047 at the Neurology Event at RedEye on October 23. Take the opportunity to listen to a very interesting live presentation and learn more about PN6047, the unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. PN6047 demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. These findings suggest a promising path forward in the field of pain management.
Read more
PharmNovo at the LSX Nordic Congress
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one of 68 companies that have recently been awarded by EIC for up to 17.5 MEUR (2.5 MEUR grant and up to 15 MEUR equity) from a total of 969 applicants is a strong validation of the potential of the phase II ready asset PN6047 and of PharmNovo. Take the opportunity to listen to the presentation here:
Read more
17.5 MEUR blended funding from EIC
PharmNovo is very pleased to announce that we have been awarded a 2.5 MEUR grant and an opportunity for up to 15 MEUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read more
PharmNovo presenting at the Global Forum
On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read more